Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.

Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.

Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.

Dermatology Times previews the research, clinical updates, late-breaking data, and therapeutic advances to watch at EADV 2026 in Vienna.

Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.

The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.

Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.

The final session of the Cutaneous Oncology Workshop explored advances in systemic therapy, management of immunotherapy-related skin reactions, and the role of radiation.